IMNN
Imunon, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.58
+1.28%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | 500.0K |
| Cost of Revenue | 166.5K | — | — | — | — |
| Gross Profit | (166.5K) | — | — | — | 500.0K |
| Operating Expenses | |||||
| R&D Expense | 8.2M | 7.8M | 11.6M | 11.3M | 11.7M |
| SG&A Expense | 2.0B | 6.9M | 7.5M | 9.7M | 13.7M |
| General & Admin Expense | 2.0B | 6.9M | 7.5M | 9.7M | 13.7M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (2.0B) | — | — | — | — |
| Total Operating Expenses | 14.7M | 14.7M | 19.1M | 21.0M | 25.4M |
| Cost and Expenses | 14.8M | 14.7M | 19.1M | 21.0M | 25.4M |
| Operating Income (EBIT) | (14.8M) | (14.7M) | (19.1M) | (21.0M) | (24.9M) |
| Non-Operating | |||||
| Interest Income | 175.6K | 155.7K | 450.2K | 725.8K | 502.6K |
| Interest Expense | 77.3K | — | — | 197.1K | 5.0M |
| Net Interest Income | 98.3K | 155.7K | 450.2K | 528.7K | (4.5M) |
| Other Non-Op Income/Expense | 120.5K | 155.7K | 512.2K | 235.1K | (12.5M) |
| Non-Operating Income (excl Interest) | (197.8K) | (155.7K) | (512.2K) | (432.1K) | 7.5M |
| EBT (Pre-Tax Income) | (14.7M) | (14.5M) | (18.6M) | (20.8M) | (37.5M) |
| Income Tax Expense | — | — | — | (1.3M) | (1.6M) |
| Bottom Line | |||||
| Net Income | (14.7M) | (14.5M) | (18.6M) | (19.5M) | (35.9M) |
| Earnings from Cont. Ops | (14.7M) | (14.5M) | (18.6M) | (19.5M) | (35.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (14.7M) | (14.5M) | (18.6M) | (19.5M) | (35.9M) |
| Per Share | |||||
| Basic EPS | ($4.53) | ($6.83) | ($21.10) | ($28.14) | ($65.55) |
| Diluted EPS | ($4.53) | ($6.83) | ($21.10) | ($28.14) | ($65.55) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.91 |
| Shares | |||||
| Basic Shares Outstanding | 5.2M | 2.1M | 882292 | 693474 | 547627 |
| Diluted Shares Outstanding | 5.2M | 2.1M | 882292 | 693474 | 547627 |
| Profitability Metrics | |||||
| EBITDA | (14.1M) | (13.8M) | (17.9M) | (19.9M) | (31.7M) |
| D&A | 572.8K | 698.9K | 718.1K | 720.0K | 731.6K |
| EBIT | (14.6M) | (14.5M) | (18.6M) | (20.6M) | (32.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026